The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [41] Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
    Wu, Yu Shen
    Shui, Lin
    Shen, Dan
    Chen, Xiaopin
    ONCOTARGET, 2017, 8 (06) : 10703 - 10713
  • [42] Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials
    Ye, Qing
    Chen, Hong-Lin
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (03) : 655 - 666
  • [43] Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
    Li, Shan
    Sun, Shanquan
    Xiang, Hui
    Yang, Jing
    Peng, Minyong
    Gao, Qing
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [44] The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
    Guo, Xiao Xia
    Wu, Hong Li
    Shia, Hong Yun
    Su, Lei
    Zhang, Xi
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2553 - 2562
  • [45] Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials
    Li, Weibing
    Wang, Hongbiao
    Li, Xuyuan
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (11) : 1443 - 1452
  • [46] BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
    Li, Shan
    Tao, Li
    Dai, Haiyun
    Gong, Xue
    Zhuo, Yuguo
    Xiang, Hui
    Zhao, Yueyang
    Gao, Qing
    Deng, Liang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
    Xie, Yao
    Zhou, Fei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Neoadjuvant Radiotherapy for Rectal Cancer: Meta-analysis of Randomized Controlled Trials
    Nuh N. Rahbari
    Heike Elbers
    Vasileios Askoxylakis
    Edith Motschall
    Ulrich Bork
    Markus W. Büchler
    Jürgen Weitz
    Moritz Koch
    Annals of Surgical Oncology, 2013, 20 : 4169 - 4182
  • [49] PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials
    Al Hadidi, Samer
    Aburahma, Ahmed
    Badami, Sunil
    Upadhaya, Sunil
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (04) : 226 - 234
  • [50] Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
    Ma, Jiao
    Deng, Hongyong
    Li, Jiajia
    Hu, Shaopu
    Yang, Yanping
    Liu, Sheng
    Han, Xianghui
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3061 - 3078
12345